Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback
NCT02966665Phase 1Recruiting
- Start
- Sep 2008
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 1 trial of NG-monomethyl-L-arginine, BQ-123, fexofenadine, ranitidine, Angiotensin II and 10 more in chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH), heart failure (HF) and 1 more (7 arms). Primary endpoint: Change in Limb Blood Flow at 1 hour. Started Sep 2008; status: recruiting.
02
Drugs
NG-monomethyl-L-arginineBQ-123fexofenadineranitidineAngiotensin II
03
Conditions
chronic obstructive pulmonary disease (COPD)pulmonary arterial hypertension (PAH)heart failure (HF)hypertension (HTN)
Beyond the preview
Go deeper on NCT02966665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966665.